Fresh analysis suggests that people who discontinue new weight-loss injections like Mounjaro or Wegovy may regain shed pounds at a significantly accelerated pace than those who stop traditional lifestyle plans.
Findings released in a major health publication points out that while overweight people can lose about a fifth of their total mass while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Users using these treatments should be aware of the potential of fast rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of recovery means a reversion to starting weight in about one and a half years.
Weighing Treatments
The analysis, which reviewed dozens of studies involving thousands of participants, contrasted the effects of these new drugs with conventional dieting.
The team emphasize that individuals who lose weight through diet and exercise typically see a less rapid weight regain—around 0.1 kg a month—once they finish.
The Reason for the Quick Regain
Nutrition scientists propose the mode of action of the drugs explains the amplified weight return.
These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making binge eating much more probable."
A Lifelong Disease?
Health authorities advise the injections for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals contend that, considering the likelihood of relapse, the therapy might need to be life-long.
This view is supported by drug manufacturers, who note that the findings "highlight the persistent nature of excess weight," comparing it to managing diseases like hypertension.
Patient Accounts
Individuals who have discontinued the medication report a sudden return of appetite.
"It was like something activating and you become starving," described a patient.
This challenge is worsened if individuals have not adopted permanent lifestyle or habit changes during treatment.
Significant Adoption
Figures suggest that a significant number of adults in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is more common among females than males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a permanent fix and lasting health benefits hinges on integrated behavioural management.
